---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-079601"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:12:52.416252+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics receives Nasdaq MVLS deficiency notice; must regain compliance by Jan 7, 2025

## Summary
- Nasdaq notified Gain on June 11, 2024, that MVLS was below $50M minimum required for Global Market listing.
- Company has 180 days (through Jan 7, 2025) to achieve MVLS >= $50M for ten consecutive business days.
- Failure to comply may lead to delisting; company could appeal or apply to transfer to Nasdaq Capital Market.
- Gain intends to monitor and take reasonable measures but cannot assure compliance.

## SEC filing metadata
- accession: 0001104659-24-079601
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924079601/0001104659-24-079601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924079601/tm2419326d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-079601
- JSON: https://secwatch.observer/filing/0001104659-24-079601.json
- Plain text: https://secwatch.observer/filing/0001104659-24-079601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.